Philochem AG Seibersdorf Labor GmbH and Isotopia announce supply development and manufacturing agreements

Collaboration allows Philochem to secure access to 177Lutetium N.C.A., a medical isotope used in multiple clinical trials for radiopharmaceutical therapies in areas of high unmet medical needs and CMO manufacturing for lead candidate Philochem, Seibersdorf Laboratories and Isotopia Molecular Imaging have today announced that they have signed agreements that will help advance the next generation of Radiopharmaceutical Therapies for cancer treatment. Under these agreements, Isotopia will supply high quality 177 Lu-n.c.a to Seibersdorf Laboratories for the purpose of conducting development and manufacturing activities for Philochem's proprietary therapeutic candidate, OncoFAP-23. OncoFAP-23 is a novel small molecule ligand developed for Targeted Radionuclide Therapy which selectively binds to Fibroblast Activation Protein (FAP), an antigen expressed in a variety of solid human malignancies, while being undetectable in most healthy tissues. Philochem's scientists demonstrated that 177Lu-OncoFAP-23 exhibits, in pre-clinical models, a very high and selective tumor uptake and with a significantly extended residence time at the site of disease, compared to other 177Lu-FAP-ligands. 177Lu n.c.a is used in Targeted Radionuclide Therapy in the field of Precision Medicine in Oncology. By binding n.c.a. 177Lu isotopes to tumor-specific targeting molecules, the resulting radiopharmaceutical targets the tumor and delivers precise cell-killing radiation that spares normal healthy tissue. Isotopia has developed a reliable and unique GMP method to produce a highly pure form of 177Lu. 177Lu n.c.a contains no Mercury (Hg) and no metastable 177Lu-m, therefore there is no need for cost intensive clinical waste management. Seibersdorf's CEO, Martina Schwaiger stated: "The new agreement is a great opportunity for our team and we are pleased to be working with Philochem and Isotopia Molecular Imaging on this important sector of medical care." Sammuele Cazzamalli, PhD, Head of Small Molecule Therapeutics at Philochem commented: " We are delighted to start working with Isotopia and Seibersdorf Laboratories on the manufacturing of our Targeted Radioligand Therapeutics. This collaboration is important to pursue Philochem's bench-to-bedside translational research, with competitive timelines, on our novel best-in-class 177Lu-OncoFAP-23." "This three-way collaboration demonstrates the ability to provide the full support for clinical development" stated Keren Moshkoviz, Director of Business Development at Isotopia. "Isotopia's aim is to play a significant role in early developments that will benefit patients in the future. We try to build a platform that can drive new products into the clinic in a simple and agile way About Philochem and the Philogen Group Philochem is a fully owned subsidiary of the Philogen Group, a Swiss-Italian clinical-stage biotechnology company listed on the Italian Stock Exchange. Philogen is engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to selectively deliver bioactive agents (such as radionuclides, cytokines, or drugs) to the site of disease using antibodies or small organic ligands. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem near Zurich, Switzerland. Philogen has signed agreements with several major pharmaceutical companies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!